Additional Proxy Soliciting Materials (definitive) (defa14a)
August 11 2022 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
Filed by the Registrant |
x |
|
|
Filed by a Party other than the Registrant |
¨ |
Check the appropriate box:
|
¨ |
Preliminary Proxy Statement |
|
¨ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
¨ |
Definitive Proxy Statement |
|
¨ |
Definitive Additional Materials |
|
x |
Soliciting Material under §240.14a-12 |
SYNTHETIC BIOLOGICS, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if
Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |
Explanatory Note
On August
11, 2022, Synthetic Biologics, Inc. (the “Company”) held its 2022 Second Quarter Investor Conference Call during which a reference
was made to the Company’s 2022 Annual Meeting of Stockholders to be held on September 30, 2022. A copy of the transcript of the
relevant part of the conference call is included in this Schedule 14A. This Schedule 14A supplements the Preliminary Proxy
Statement filed by the Company with the U.S. Securities and Exchange Commission on August 3, 2022.
*****
Synthetic
Biologics, Inc.
2022 Second
Quarter Investor Conference Call
Publication date: August 11,
2022
Relevant Section of Transcript
as follows:
Financial Updates
Before turning to our financial results, I would
remind you that the Company’s common stock began trading on a split-adjusted basis on July 25, 2022. The reverse stock split was
effected to ensure that we could continue to meet the per share price requirements of the NYSE American stock exchange. We believe maintaining
our listing on NYSE American is important to the Company’s performance, corporate visibility and will provide greater flexibility
with respect to future capital market access.
On July 29th , with MSD Credit Opportunity
Master Fund, we closed a $3 million private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of
Series D convertible preferred stock. Each share of Series C and Series D preferred stock has a purchase price of $8.00. Each share of
Series C and Series D preferred stock is convertible into shares of the Company’s common stock at an initial conversion price of
$1.22 per share. The proceeds from the stock offering will further support the advancement of our clinical development programs. The purpose
of this financing was twofold: first, the structure of the transaction will aid us administratively during our upcoming shareholder meeting
to ensure that we have the necessary quorum for the meeting, and the votes needed to help pass key initiatives that we believe are critical
to our long-term success and viability; and second, we have added a significant and highly respected institutional investor who is very
supportive of the management team, our technologies and our strategy.
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Dec 2023 to Dec 2024